
Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trial

In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest growing disease segments

Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product

By analyzing the mutation sites of N protein and their proportion according to the coronavirus sequences released by the GISAID database, full-length N protein recombinant

We are delighted to announce the receipt of the MDSAP certificate today. This highlights our firm and long lasting commitment to the highest quality standards.

Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by launching its VYRA™ CoV2Flu

Halifax, Nova Scotia, 17 December 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective

Halifax, Nova Scotia, 14 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces a financial package of over $5.23 million to support the Company’s
Contacts Investor Relations
For more information about MedMira or inquiries related to Investor Relations, please contact us. Our Investor relations team will get back to you immediately.
Corporate Headquarters
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada
Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com